Earnings Insights · BIIB · Q3 FY2026
Biogen Q3 2026 Earnings: Apellis Lifts Revenue Growth, but Acquisition Costs Depress EPS
By AlgovestIQ ResearchPublished
Read Biogen’s results announcement (Form 8-K, filed Oct 28, 2026)
Key earnings findings
Biogen (BIIB) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Biogen reported Q3 FY2026 revenue of $2.80B against the $2.63B analyst estimate, a 6.4% beat, and EPS of $2.62 against the $1.99 analyst estimate, a 31.7% beat.
- Biogen raised the lower end of its full-year 2026 non-GAAP diluted EPS guidance range to $12.20 to $13.00, from its prior range of $12.00 to $13.00.
- BIIB closed at $244.05 on Oct 28, 2026, down 3.4% from $252.73 on Oct 27, 2026, the last close before the results were released.
Sources: Biogen results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Biogen beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from 1.9% to 13.6%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Biogen reported Q3 2026 revenue of $2.8B, up 11% year over year, as its Growth Portfolio expanded 49% and received its first full-quarter contribution from the Apellis acquisition. GAAP diluted EPS swung to a loss of $0.14 from earnings of $3.17 a year earlier, while non-GAAP EPS declined 46% to $2.62, largely reflecting $284M of acquired IPR&D, upfront and milestone expense.
The quarter supports Biogen’s claim that its commercial base is shifting away from its declining multiple sclerosis franchise. However, the quality of the growth matters: Apellis added a substantial acquired revenue contribution, while several products also benefited from inventory movements, conversion-related dosing, or pricing items that management expects to normalize in Q4.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $2.8B | +11% YoY |
| Total revenue, constant currency | $2.8B | +10% YoY |
| Product revenue | $2.1B | +13% YoY |
| Growth Portfolio revenue | $1.26B | +49% YoY |
| Core Pharmaceutical revenue | $2.0B | +18% YoY |
| GAAP diluted EPS | $(0.14) | vs. $3.17 |
| Non-GAAP diluted EPS | $2.62 | -46% YoY |
| Multiple sclerosis revenue | $919M | -13% YoY |
| Rare disease revenue | $676M | +27% YoY |
| Specialized immunology revenue | $243M | New |
| Biosimilars revenue | $166M | -16% YoY |
| Anti-CD20 program revenue | $497M | +1% YoY |
| Alzheimer’s collaboration revenue | $68M | +60% YoY |
| Operating cash flow | $641M | vs. $1.3B |
| Free cash flow | $600M | vs. $1.2B |
| Cash and cash equivalents | $1.3B | — |
| Total debt | $7.7B | — |
| Net debt | $6.4B | — |
The Bigger Story
Biogen’s revenue mix is changing faster than its headline 11% growth rate alone suggests. The Growth Portfolio generated $1.26B, or 63% of Core Pharmaceutical revenue, and exceeded the legacy MS franchise for another quarter. SPINRAZA, LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY, SYFOVRE and EMPAVELI are now carrying more of the company’s growth burden as older MS products contract.
The Apellis acquisition materially accelerated that transition. SYFOVRE and EMPAVELI contributed $243M in Q3 specialized immunology revenue, Biogen’s first full quarter owning the products. Management said the transaction was roughly neutral on an operating basis during the quarter and expects it to become accretive to non-GAAP EPS in 2027, supported by at least $250M in run-rate synergies by the end of 2027.
That outlook is constructive, but the acquisition also increased leverage and interest expense. It means the investment case now depends not just on the growth of inherited Apellis assets, but also on Biogen’s ability to sustain demand for those products, realize cost synergies, and reduce debt while funding a larger late-stage pipeline.
Revenue and Operating Performance
Product revenue increased 13% to $2.1B, led by new and growing products, while anti-CD20 program revenue was effectively flat at $497M. Alzheimer’s collaboration revenue rose 60% to $68M, reflecting Biogen’s share of LEQEMBI economics.
Growth Portfolio Strength Was Broad, Though Not Entirely Organic
SPINRAZA revenue increased 23% to $461M. The primary driver was conversion to the higher-dose regimen, including one-time transition doses for patients moving from the lower-dose product. Management said the pace of conversion exceeded expectations, but also cautioned that the related benefit will fade as the conversion cohort matures. It expects Q4 global SPINRAZA revenue to increase by a mid-single-digit percentage from Q4 2025.
LEQEMBI global in-market sales, recorded by Eisai, rose 67% to $202M. U.S. in-market sales were $107M. Management described early adoption of LEQEMBI IQLIK, the subcutaneous formulation, as encouraging, particularly among prescribers who had not previously used an anti-amyloid therapy. Broader uptake remains tied to reimbursement: management expects at least 50% of covered lives to have coverage for both initiation and maintenance administration starting in 2027.
Rare disease revenue grew 27% to $676M. SPINRAZA was the largest contributor, while SKYCLARYS increased 34% to $178M and QALSODY rose 42% to $38M. SKYCLARYS demand expanded in the U.S. and internationally, though Q3 revenue also included an approximately $12M inventory build that management expects to reverse in Q4.
ZURZUVAE revenue rose 53% to $84M, reflecting continued demand growth. QALSODY’s 42% increase was driven by U.S. and international demand.
Apellis Products Added Scale
SYFOVRE generated $191M, up 27% from the prior-year revenue reported by Apellis, while EMPAVELI contributed $52M, up 92% on the same comparison basis. SYFOVRE commercial injection volume rose 18% year over year and 7% sequentially, reaching its highest quarterly level since launch.
Management attributed SYFOVRE’s growth to deeper prescribing, more physicians adopting treatment, and improving acceptance of treatment for geographic atrophy. However, revenue included an estimated $11M inventory build, and management expects a one-time price benefit tied to the co-pack launch to normalize in Q4. It still expects Q4 SYFOVRE revenue to rise by a mid-single-digit percentage versus the $155M reported by Apellis in Q4 2025.
EMPAVELI’s sequential growth was led by demand in C3 glomerulopathy and primary IC-MPGN. Management said it is adding a dedicated sales force for the more competitive PNH market, where sequential demand was stable.
Legacy MS Remains a Drag
MS revenue fell 13% to $919M. TECFIDERA declined 51% to $82M, while VUMERITY fell 11% to $192M as U.S. Part D plans adopted tighter formulary management. Management expects VUMERITY’s Q4 revenue to be roughly flat sequentially or up a mid-single-digit percentage from Q4 2025, but characterized the formulary change as establishing a lower base for future growth.
TYSABRI rose 1% to $437M. U.S. revenue benefited from inventory dynamics, while management said the European business remained stable, aided by the subcutaneous formulation. The resilience of TYSABRI is useful for cash generation, but it does not alter the broader decline across the MS franchise.
Profitability and Margins
The revenue increase did not translate into higher earnings. GAAP net income swung to a $20.6M loss from $466.5M of income a year earlier, producing a GAAP diluted loss of $0.14 per share.
The largest discrete factor was $284M of acquired IPR&D, upfront and milestone expense, compared with $2M in Q3 2025. The earnings release identified the RayThera acquisition as the primary source of this charge, while management on the call referred to the charge as largely associated with another acquisition. Regardless of attribution, the expense reduced non-GAAP diluted EPS by approximately $1.70 and GAAP EPS by approximately $1.65, according to management.
Non-GAAP diluted EPS fell to $2.62 from $4.81. Even excluding the acquired IPR&D charge, profitability faced pressure from higher operating costs and interest expense.
Non-GAAP R&D expense rose 31% to $567M, reflecting clinical spending on felzartamab, salanersen and litifilimab, the inclusion of Apellis operations, and lower R&D funding from Royalty Pharma. Non-GAAP SG&A increased 23% to $730M, driven by Apellis commercial and management operations and spending behind U.S. and international launches.
Non-GAAP cost of sales was 20% of revenue, unchanged from a year earlier. GAAP cost of sales also represented 27% of revenue, but included higher inventory fair-value step-up amortization from the Reata and Apellis acquisitions.
Demand, Customers and Pricing
The commercial picture was strongest in products where Biogen is expanding treatment adoption rather than simply defending a mature franchise.
For SYFOVRE, management believes patient and physician education can reduce discontinuations after the first injection. It said many patients do not fully understand that the product is designed to slow disease progression rather than immediately improve vision. Biogen plans to launch a direct-to-consumer campaign next year, subject to management’s plans, to support patient awareness and treatment persistence.
LEQEMBI IQLIK could broaden access to anti-amyloid therapy if payer coverage expands as expected in 2027. Management said the formulation is gaining use among new prescribers, but it remains early in the launch and reimbursement is still a gating factor.
SKYCLARYS growth is being supported by patient-finding efforts, including artificial-intelligence-enabled identification tools, according to management. The next potential commercial inflection is a pediatric expansion, although no timing or regulatory outcome was provided.
What is Biogen’s FY 2026 guidance?
Biogen raised the lower end of its full-year 2026 non-GAAP diluted EPS guidance range to $12.20 to $13.00, from its prior range of $12.00 to $13.00.
Management continues to expect:
- Total revenue to increase by a mid-single-digit percentage in 2026 versus 2025.
- Combined non-GAAP R&D and SG&A expense of approximately $4.95B for the full year.
- Approximately $3.20 per share of acquired IPR&D, upfront and milestone charges in 2026.
- Approximately $0.55 per share of dilution from the Apellis acquisition.
The higher EPS floor reflects stronger business performance and faster-than-expected capture of Apellis synergies. Management also expects about $50M of acquired IPR&D expense in Q4.
Investors should note that management expects Q4 revenue to be affected by the normalization of SPINRAZA transition dosing, SKYCLARYS and SYFOVRE inventory movements, a SYFOVRE pricing benefit, and lower contract-manufacturing revenue due to batch timing.
Balance Sheet, Cash Flow and Capital
Biogen generated $641M of operating cash flow and $600M of free cash flow in Q3, compared with $1.2B of free cash flow a year earlier. The year-over-year decline reflects the higher operating-cost and working-capital demands of the business, though the company remained cash generative.
At September 30, Biogen held $1.3B in cash and cash equivalents against $7.7B of total debt, resulting in net debt of approximately $6.4B. Cash declined from $3.0B at year-end 2025, while total debt increased from $6.3B, underscoring the financial impact of acquisitions.
Management repaid $400M of Apellis-related term loans in Q3 and said it has repaid $600M in total. It expects to repay the remaining $1.4B of those term loans by the end of 2027. Reducing this debt while sustaining pipeline investment will be an important test of the acquisition’s financial benefits.
What Investors Should Watch
1. Apellis Revenue Durability and Synergy Delivery
SYFOVRE and EMPAVELI are now meaningful contributors to growth. Investors should monitor demand after Q3 inventory and pricing benefits reverse, as well as progress toward the targeted $250M in run-rate synergies by the end of 2027.
2. SPINRAZA Growth After Conversion Dosing Normalizes
High-dose conversion drove a meaningful Q3 tailwind. The key question is whether patient retention, switchbacks from competitors, and new patient starts can sustain growth once one-time transition doses diminish.
3. MS Franchise Erosion and VUMERITY Formulary Pressure
MS revenue declined 13%, and VUMERITY is dealing with stricter Part D formulary management. Stability in TYSABRI helps, but investors should watch whether deterioration in older MS products accelerates faster than the Growth Portfolio can offset it.
4. Late-Stage Clinical Readouts
Management expects TOPAZ-1 and TOPAZ-2 Phase 3 data for litifilimab in SLE in the first half of December 2026. Additional Phase 3 readouts are expected for litifilimab in CLE and felzartamab in antibody-mediated rejection in the first half of 2027, followed by zorevunersen in Dravet syndrome in Q3 2027. These programs are central to whether Biogen can add internally developed growth beyond acquired products.
5. Leverage and Free Cash Flow
The company remains cash generative, but net debt stands at $6.4B following the Apellis acquisition. Free cash flow recovery and term-loan repayment will determine how much flexibility Biogen has for further business development and commercial investment.
AlgovestIQ Takeaway
Biogen delivered a stronger revenue quarter, and its portfolio transition is becoming visible in the numbers. Growth Portfolio revenue rose 49%, now represents nearly two-thirds of Core Pharmaceutical revenue, and helped offset continued erosion in the legacy MS business. The Apellis acquisition immediately added scale in specialized immunology and appears to be integrating faster than management initially expected.
The earnings picture was weaker than the revenue trajectory because of acquired IPR&D charges, acquisition-related amortization, restructuring costs, higher R&D and SG&A spending, and greater interest expense. Some of those pressures are acquisition-related and non-recurring, but the underlying cost base is also rising as Biogen funds pivotal studies and prepares for possible launches.
The central investment question is whether Biogen can convert today’s acquired and commercial growth into a more durable, internally reinforced growth platform. SYFOVRE, EMPAVELI, SPINRAZA high-dose conversion, LEQEMBI IQLIK adoption, and SKYCLARYS expansion all offer near-term opportunities, but several were assisted by temporary inventory, pricing, or dosing effects in Q3.
Evidence that would strengthen the thesis includes sustained demand after those factors normalize, delivery of Apellis synergies and debt reduction, and positive Phase 3 data from the company’s immunology and rare-disease pipeline. Conversely, faster MS erosion, weaker SYFOVRE persistence, slower reimbursement-driven LEQEMBI adoption, or disappointing pivotal data would leave Biogen more dependent on acquired assets and a smaller set of commercial growth drivers.
How did BIIB stock react?
BIIB closed at $244.05 on Oct 28, 2026, down 3.4% from $252.73 on Oct 27, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Oct 27, 2026 (before release) | $252.73 | — |
| Oct 28, 2026 | $244.05 | -3.4% |
| Oct 29, 2026 | $249.65 | -1.2% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- LLYEli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B QuarterOct 29, 2026
- MRKMerck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPSOct 29, 2026
- GILDGilead Q3 2026 Earnings: Base Business Growth Accelerates as Biktarvy Pricing Risk Comes Into FocusOct 29, 2026
- ABBVAbbVie Q3 2026 Earnings: Skyrizi and Rinvoq Drive Another Guidance IncreaseOct 30, 2026
- PFEPfizer Q3 2026 Earnings: Core Products Offset COVID Declines as Guidance RisesNov 3, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Biogen Q3 FY2026 earnings call transcript, as of Oct 28, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Biogen Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 28, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 28, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.